To,
The Members,
Your Directors have pleasure in presenting the 24th Annual
Report on the business and operations of the Company along with the audited financial
statements (Consolidated as well as Standalone) for the financial year ended March 31,
2026.
1. Financial Summary of the Company
|
Standalone J |
In Million |
Consolidated J |
In Million |
Particulars |
2025-26 |
2024-25 |
2025-26 |
2024-25 |
Total Revenue |
17581 |
14,408 |
39308 |
30,670 |
Profit/(Loss) Before Interest and
Depreciation |
5245 |
4,732 |
8282 |
8,148 |
| Less: Finance Cost |
787 |
232 |
2025 |
903 |
| Less: Depreciation and amortization expenses |
861 |
577 |
2832 |
1,772 |
Profit before share of loss of associate
and Tax |
3597 |
3,923 |
3425 |
5,473 |
| Add: Share of Profit / (Loss) in associate |
|
- |
26 |
- |
| Add: Exceptional items |
(70) |
108 |
(112) |
108 |
Profit before Tax |
3527 |
4,031 |
3339 |
5,581 |
Less: Income Tax |
|
|
|
|
| - Current Tax |
750 |
951 |
1362 |
1,495 |
| - Deferred Tax Charge |
175 |
47 |
(463) |
(47) |
| - Tax Pertaining to earlier years |
(5) |
4 |
20 |
(15) |
Profit After Tax |
2607 |
3,029 |
2420 |
4,148 |
| Add: Other Comprehensive Income |
0 |
(13) |
2 |
(23) |
Total Comprehensive Income |
2607 |
3,016 |
2422 |
4,125 |
2. Results of operations/state of company's affair
During the year under review, the total revenue on standalone basis
increased to H 17,581 million in FY26 compared to H 14,408 million in the previous
year, an increase by 22%. The profit after tax for the year decreased to H 2607 million in
FY26 compared to H 3,029 million in the previous year, decrease by 14%.
During the year under review, the consolidated total revenue of the
Company increased to H 39,308 million in FY26 compared to H 30,670 million, an increase of
28% Profit after tax for the group decreased to H 2420 million in FY26 compared to 4,148
million in the previous year, decrease by 42%.
3. Consolidated Financial Statements
In accordance with Companies Act, 2013 ("the Act") and Ind AS
110 - Consolidated Financial Statements read with Ind AS 28 - Investment in Associates and
Joint ventures, the audited consolidated financial statements form part of the Annual
Report.
In terms of provision to sub section (3) of Section 129 of the Act, the
salient features of the financial statements of the Subsidiaries and Associates are set
out in the prescribed Form AOC-1, which forms a part of the Annual Report.
In accordance with Section 136 of the Act, the audited financial
statements, including the consolidated financial statements of the Company and audited
accounts of the subsidiaries are available at the Company's website:
https://www.kimshospitals. com/investors/.
The documents will also be available for inspection during business
hours at the registered office of the Company.
4. Change in the nature of the business, if any:
There was no change in the nature of Business during the year.
5. Dividend
The Company is not proposing any Dividend during the year.
6. Transfer of Reserves
The Company has recorded a profit of H 2,607 million (Standalone) for
the period 2025-26 and the same was transferred to the head of other Equity.
7. Share Capital
The paid-up share capital as of March 31, 2026, is 80,02,77,870.
During the year under review, the Company has not issued shares with
differential voting rights nor granted stock options nor sweat equity.
As of March 31, 2026, the details of shareholding in the Company held
by the Directors are set out in the Corporate Governance Report forming part of the
Board's Report and none of the directors hold convertible instruments of the Company.
8. Directors and Key Managerial Personnel
Composition of the Board: The Board of Directors ("the
Board") of the Company consists of an optimal combination of Executive,
Non-Executive and Independent Directors which represent a mix of professionalism,
knowledge and experience.
The Board brings in guidance, leadership, and an independent view to
the Company's management while discharging its fiduciary responsibilities, thereby
ensuring that management adheres to the ethics, transparency, and disclosure norms.
As of the date of this report, the Board comprises of 9 (Nine)
Directors, of whom, 3 (Three) are Executive Director and 6 (Six) are Non-Executive
Directors. Amongst the Non-Executive Directors, 5 (Five) are Independent Directors and 1
(one) is Non- Independent Director. The Non-Executive Directors bring an external and
wider perspective in Board's deliberations and decisions. The size and composition of
the Board conforms to the requirements of the Companies Act, 2013.
Independent Directors
Your Independent Directors fulfill all the conditions for being
Independent to the Company, as stipulated under the Companies Act, 2013. All Independent
Directors have given the declaration that they meet the criteria of Independence as laid
down under section 149(6) of the Companies Act, 2013.
The Board is of the opinion that the above Independent Directors
possess requisite integrity, experience and expertise (including the proficiency).
Meetings of Independent Directors : The Independent Directors
had a meeting on 26.03.2026.
Key Managerial Personnel and Change in Directors during the year
Ms. Y. Prameela Rani completed her initial three-year term as an
Independent Director of the Company on May 18, 2025. In recognition of her valuable
contributions and continued guidance, the Board of Directors, at its meeting held on May
12, 2025, approved her reappointment as an Independent Director for a further term of five
years. The said reappointment was subsequently approved by the shareholders by way of
special resolution through a postal ballot, the results of which were declared on July 24,
2025.
Retirement by Rotation
Pursuant to Section 152 of the Companies Act 2013, Ms. Dandamudi
Anitha, Whole-Time Director retires by rotation at the ensuing Annual General Meeting and
being eligible offers herself for re-appointment.
9. Board Functioning & Meetings
The Board and Committee meetings are pre-scheduled and a tentative
calendar of the meetings is finalized in consultation with the Directors to facilitate
them to plan their schedule. However, in case of urgent business needs, approval is taken
by passing resolutions through circulation. During the year under review, 9 (Nine) board
meetings were held. The intervening gap between the Meetings was within the period
prescribed under the Companies Act, 2013.
The details of the meetings including the composition of various
committees are provided in the Corporate Governance Report. In terms of requirements under
Schedule IV of the Act and Regulation 25(3) of the SEBI Listing Regulations, one separate
meeting of the Independent Directors was held during the year.
10. Nomination and Remuneration Policy
The Board has, on the recommendation of the Nomination &
Remuneration Committee, approved a policy for selection and appointment of Directors,
Senior Management and their remuneration. The Remuneration Policy is stated in the
Corporate Governance Report.
11. Annual Return
As required pursuant to section 92(3) of the Companies Act, 2013 and
rule 12(1) of the Companies (Management and Administration) Rules, 2014, draft Annual
Return is uploaded on the website of the Company at https://www.kimshospitals.
com/investors/.
12. Details of Subsidiary/Joint Ventures/Associate Companies a.
Arunodaya Hospitals Private Limited (Subsidiary Company): The subsidiary company has
recorded a total revenue of H 577 million during the financial year 2025-26.
b. KIMS Hospital Enterprises Private Limited (Subsidiary Company): The
subsidiary company has recorded a total revenue of H 4037 million during the financial
year 2025-26.
c. Iconkrishi Institute of Medical Sciences Private Limited (Subsidiary
Company): The subsidiary company has recorded a total revenue of H 1596 million during
the financial year 2025-26.
d. Saveera Institute of Medical Sciences Private Limited (Subsidiary
Company): The subsidiary company has recorded a total revenue of H 1108 million during
the financial year 2025-26.
e. KIMS Hospital Kurnool Private Limited (Subsidiary Company): The
subsidiary company has recorded a total revenue of H 1173 million during the financial
year 2025-26.
f. Sarvejana Healthcare Private Limited (Subsidiary Company): The
Subsidiary Company has recorded a total revenue of H 6823 million during the financial
year 2025-26.
g. SPANV Medisearch Lifesciences Private Limited (Subsidiary Company): The
Subsidiary Company has recorded a total revenue of H 2665 million during the financial
year 2025-26.
h. KIMS Manavata Hospitals Private Limited (Subsidiary Company): The
Subsidiary Company has recorded a total revenue of H 741 million during the financial year
2025-26.
i. KIMS Hospital Bengaluru Private Limited (Subsidiary Company):
The Subsidiary Company has recorded a total revenue of H 1024 million during the financial
year 2025-26.
j. Meda Institute of Podiatry Private Limited (Subsidiary Company): The
Subsidiary Company has recorded a total revenue of H 47 million during the financial year
2025-26.
k. KIMS Swastha Private Limited (Wholly-owned Subsidiary) - The
Wholly-owned Subsidiary company has recorded a total revenue of H 1713 million during the
financial year 2025-26.
l. Chalasani Hospitals Private Limited (Wholly-owned Subsidiary) -
The Wholly-owned Subsidiary company has recorded a total revenue of H 1080 million during
the financial year 2025-26.
m. KIMS Hospitals Private Limited is a wholly-owned subsidiary of
your Company, which is still under the process of setting up its infrastructure to run the
hospital.
The information on subsidiary Companies pursuant to Section 129(3) of
the Act read with rule 5 of the Companies (Accounts) Rules, 2014 is annexed herewith as Annexure
I in Form AOC - 1.
13. Particulars of contracts or arrangements with related parties.
All contracts, arrangements, and transactions entered into by the
Company with related parties during the financial year were conducted in the ordinary
course of business and on an arm's length basis. During the year under review, the
Company did not enter into any contract, arrangement, or transaction with related parties
that could be considered material in accordance with the Company's Policy on
Materiality of Related Party Transactions, except for those disclosed in Annexure II.
The disclosure pursuant to Clause (h) of Sub Section (3) of Section 134
of the Companies Act, 2013 and Rule 8(2) of the Companies (Accounts) Rules, 2014) as
required is enclosed as Annexure II.
The Policy on materiality of related party transactions and dealing
with related party transactions as approved by the Board may be accessed on the
Company's website https://www.kimshospitals.com/investors/. Your Directors draw the
attention of the members to the Notes to the financial statements which sets out related
party disclosures.
None of the Directors have any pecuniary relationships or transactions
vis-a-vis the Company except Dr. Bhaskara Rao Bollineni, Chairman & Managing Director
who has drawn a professional fee of H 2 million for the Financial year 2025- 26.
14. Statutory Auditors
The members at the 22nd Annual General Meeting held on
August 29, 2024, approved re-appointment of S. R. Batliboi & Associates LLP, Chartered
Accountants (Firm Registration No. 101049W/ E300004), as the Statutory Auditors to hold
office from the conclusion of the 22nd Annual General Meeting till the
conclusion of the 27th Annual General Meeting.
There are no qualifications, reservations or adverse remarks made by
the Statutory Auditors in their audit reports on the financial statements for the year
ended 31 March 2026.
15. Cost Auditors
Pursuant to Section 148 of the Companies Act, 2013 read with the
Companies (Cost Records and Audit) Rules, 2014, the Directors on the recommendation of the
Audit Committee, appointed M/s. Sagar & Associates, Cost Accountants, Hyderabad (FRN
000118) to audit the cost accounts of the Company for the financial year 2026-2027 on a
remuneration of H 6.00 Lakhs.
As required under the Companies Act, 2013, the remuneration payable to
the cost auditor is required to be placed before the Members in a general meeting for
their ratification. Accordingly, a resolution seeking Member's ratification for the
remuneration payable to M/s. Sagar & Associates, Cost Accountants, Hyderabad (FRN
000118) will be part of the Notice convening the 24th Annual General Meeting.
The Company has maintained cost records in accordance with the
provisions of the Companies Act, 2013 read with the Companies (Cost Records and Audit)
Rules, 2014 in respect of healthcare services.
16. Adequacy of Internal Financial Controls:
The Company has an Internal Control System, commensurate with the size,
scale and complexity of its operations. The scope and authority of the Internal Audit (IA)
function is defined in the Internal Audit Charter. To maintain its objectivity and
independence, the Internal Audit function reports to the Chairman of the Audit Committee
of the Board. The details of the internal control system and its terms of reference are
set out in the Management Discussion and Analysis Report forming part of the Board's
Report.
The Board of Directors has laid down internal financial controls to be
followed by the Company and the policies and procedures to be adopted by the Company for
ensuring the orderly and efficient conduct of its business, including adherence to the
Company's policies, the safeguarding of its assets, the prevention and detection of
frauds and errors, the accuracy and completeness of the accounting records, and the timely
preparation of reliable financial information. The Audit Committee evaluates the internal
financial control systems periodically.
17. Secretarial Auditors Report
The Board had in its meeting held on 12th May, 2025
appointed M/s. IKR & Associates (a Peer-Reviewed Firm), as the Secretarial Auditor for
a period of 5 years as recommended by the Audit Committee subject to Shareholders
approval. Subsequently Shareholders in 23rd Annual General Meeting held on 29th
August, 2025 approved the same. Accordingly M/s. IKR & Associates Practicing Company
Secretaries will continue till the conclusion of the Annual General Meeting to be held in
2030.
In addition, as required under the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, the secretarial audit of KIMS Hospital
Enterprises Private Limited and Sarvejana Healthcare Private Limited, the material
subsidiaries, has also been carried out.
As required under Section 204 of the Companies Act, 2013 and SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, the secretarial audit
report of the Company and its material subsidiaries are enclosed as Annexure III
and
Annexure IV respectively, which forms part of this report. The
audit reports do not contain any qualifications, reservations, or adverse remarks.
18. Vigil Mechanism/Whistle Blower Policy
KIMS Code of Conduct requires directors, officers, and employees to
observe high standards of business and personal ethics in the conduct of their duties and
responsibilities. The Company has a Whistleblower Policy to enable persons who observe
unethical practice (whether or not a violation of law), or violation of the Code of
Business Conduct, other than matters covered by the POSH Policy to approach the
Whistleblower Custodian without revealing their identity, if they choose to do so. Further
the complaint can be reported to the Ombudsperson (Chairman of the Audit Committee) where
the Complainant feels that the complaint has not been addressed or actioned in a timely
and appropriate manner. Also, if the complaint is against any member of the Whistleblower
Committee or the Executive Council, the same would be made to the Ombudsperson. This
Policy governs reporting and investigation of allegations that are breach of Code of
Business Conduct and violation under code for prevention of Insider Trading.
The policy on Vigil Mechanism and Whistle Blower Policy has been posted
on the website of the Company https://www.kimshospitals.com/investors/.
19. Dividend Distribution Policy:
The said Dividend Distribution policy is placed on the website of the
Company https:// www.kimshospitals.com/investors/.
20. Performance Evaluation of the Board and the Directors
Pursuant to the provisions of the Companies Act, 2013 and SEBI Listing
Regulations, the Board has carried out an annual performance evaluation of the directors
individually, Board, Chairperson and Committees.
The evaluation is performed by the Board, Nomination and Remuneration
Committee and Independent Directors with specific focus on the performance and effective
functioning of the Board and Individual Directors.
The manner in which the evaluation has been carried out has been
explained in the Corporate Governance Report.
21. Risk Assessment and Minimization.
The Board of Directors had constituted a Risk Management Committee to
identify elements of risk in different areas of operations and to develop a policy for
actions associated with mitigating the risks. The Committee on a timely basis informed the
members of the Board of Directors about risk assessment and minimization procedures and in
the opinion of the Committee there was no risk that may threaten the existence of the
Company. The details of the Risk Management Committee are included in the Corporate
Governance Report.
22. Material changes and commitments, if any, affecting the financial
position of the company which have occurred between the end of the financial year of the
company to which the financial statements relate and the date of the report.
There are no material changes and commitments affecting the financial
position of the Company that have occurred between the end of the financial year of the
Company to which the financial statements relate and the date of the report i.e. between
March 31, 2025, to March 31, 2026.
23. Details of significant and material orders passed by the regulators
or courts or tribunals impacting the going concern status and the company's
operations in the future.
There are no significant and material orders passed by the regulators
or courts or tribunals impacting the going concern status and company operations in the
future.
24. The details of an application made or any proceeding pending under
the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year along with their
status as at the end of the financial year:
There are no applications made or pending under the Insolvency and
Bankruptcy Code, 2016 during the year under review.
25. The details of the difference between the amount of the valuation
done at the time of one-time settlement and the valuation done while taking a loan from
the Banks or Financial Institutions along with the reasons thereof :
Not Applicable, as the Company has not done any one-time settlement
during the year under review.
26. Deposits
Your Company has not accepted any deposits from the public covered
under Chapter V of the Act, during the year under review.
27. Particulars of loans, guarantees, or investments under section 186
The Company makes investments or extends loans/ guarantees to its
wholly-owned subsidiaries/ Subsidiaries for their business purposes. Details of loans,
guarantees and investments covered under Section 186 of the Act, along with the purpose
for which such loan or guarantee was proposed to be utilised by the recipient, form part
of the notes to the financial statements provided in this Integrated Annual Report.
28. Particulars of employees and related disclosures
Disclosure pertaining to remuneration and other details as required
under Section 197(12) of the Act read with Rule 5(1) of the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014 is annexed to the Report as Annexure
V.
In terms of Section 197(12) of the Act, read with Rule 5(2) and 5(3) of
the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a
statement showing the names and other particulars of the employees drawing remuneration in
excess of limits set out in the said rules forms part of the Integrated Annual Report
Considering the provisions of Section 136 of the Act, the Integrated
Annual Report, excluding the aforesaid information, is being sent to the members of the
Company and others entitled thereto. The said information is available for inspection at
the registered office of the Company or through electronic mode, during business hours on
working days up to the date of the forthcoming 24th AGM, by members. Any member
interested in obtaining a copy thereof may write to the Company Secretary in this regard.
No Employee Stock Options have been granted to the employees of the
Company and thus no disclosure is required.
29. Corporate Governance
The Company is committed to maintain the highest standards of corporate
governance and adhere to the corporate governance requirements set out by SEBI. The report
on corporate governance as required under the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter Listing
Regulations), forms an integral part of this report. The requisite certificate from M/s
IKR & Associates, Practicing Company Secretaries confirming the compliance with the
conditions of corporate governance is attached to the report on Corporate Governance.
30. Management Discussion and Analysis
Management Discussion and Analysis for the year under review, as
stipulated under Regulation 34 of the Listing Regulations is presented in a separate
section forming part of the Annual Report.
31. Business Responsibility and Sustainability Report (BRSR)
As stipulated under the Listing Regulations, the Business
Responsibility and Sustainability Report describing the initiatives taken by the Company
from an environmental, social and governance perspective is attached as part of the Annual
Report.
32. Conservation of energy, technology absorption and foreign exchange
earnings and outgo
The details of conservation of energy, technology absorption, foreign
exchange earnings and outgo are as follows:
a) Conservation of energy
Particulars required under section 134(3) of the Companies Act, 2013
read with Companies (accounts) Rules, 2014 is not applicable as the Company is not energy
conservative; however your company is taking necessary steps to save the energy.
b) Technology Absorption
Over the years, your Company has brought into the country the best that
the world has to offer in terms of technology. In its continuous endeavor to serve the
patients better and to bring healthcare of international standards, your Company has
introduced the latest technology in its hospitals.
c) Foreign exchange earnings and Outgo
Your Company did not have any long-term contracts including derivative
contracts for which there were any material foreseeable losses. Your Company does not have
any unhedged foreign currency exposure as at March 31, 2026.
Foreign Exchange Earnings: Rs. 39.9 Million Foreign Exchange Outgo: Rs.
14.35 Million
33. Corporate Social Responsibility (CSR)
As per the Provisions of Section 135 of the Companies Act, 2013 read
with Rule 9 of Companies (Corporate Social Responsibility Policy) Rules, 2014, the
Corporate Social Responsibility (CSR) committee has been formed by the company. The
Committee has approved the CSR which is stated in the Corporate Governance Report.
As part of its initiatives under Corporate Social Responsibility (CSR),
the Company has undertaken projects in the areas of Rural Development, Healthcare,
Education & Skill Development and Research in Healthcare. These projects are in
accordance with Schedule VII of the Companies Act, 2013. The Report on CSR activities for
the financial year 2025-2026 is annexed herewith as Annexure VI.
34. Human Resources
Your Company treats its "human resources" as one of its most
important assets. Your Company continuously invests in attracting, retention and
development of talent on an ongoing basis. A number of programs that provide focused
people attention are currently underway.
35. Compliance with Secretarial Standards
During the year under review, the Company has duly complied with the
applicable provisions of the Revised Secretarial Standards on Meetings of the Board of
Directors (SS-1) and General Meetings (SS-2) issued by the Institute of Company
Secretaries of India (ICSI).
36. Obligation of company under the Sexual Harassment of Women at
Workplace (prevention, prohibition and redressal) Act, 2013.
In order to prevent sexual harassment of women at work place a new act,
The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act,
2013 has been notified on 9th December, 2013. Under the said Act every company
is required to set up an Internal Complaints Committee to look into complaints relating to
sexual harassment at work place of any women employee.
The company has adopted a policy for the prevention of Sexual
Harassment of Women at the workplace and has set up a Committee for the implementation of
said policy.
The Company regularly conducts awareness programs for its employees.
The following is a summary of sexual harassment complaints received and disposed off
during the year:
S.No Particulars |
Status of the no. of complaints received
and disposed off |
| 1 Number of complaints on Sexual harassment
received |
1 |
| 2 Number of Complaints disposed off during
the year |
1 |
| 3 Number of cases pending for more than
ninety days |
0 |
Maternity Benefit: The Company has duly complied with all provisions of
the Maternity Benefit Act, 1961 and has extended all statutory benefits to eligible women
employees during the year.
Constitution of Internal Complaints Committee under the Sexual
Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:
The Company has constituted an Internal Complaints Committee under the
Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.
37. Cyber Security:
The Company has established requisite technologies, processes and
practices designed to protect networks, computers, programs and data from external attack,
damage or unauthorized access. The Company is conducting training programs for its
employees at regular intervals to educate the employees on safe usage of the
Company's networks, digital devices and data to prevent any data reaches involving
unauthorized access or damage to the Company's data. The Information Technology
Department of the Company is in a constant process of taking feedback from the employees
and updating the cyber security protocols.
The Risk Management Committee and the Board of Directors are reviewing
the cyber security risks and mitigation measures from time to time.
38. Confirmation and Opinion of the Board on Independent Directors
All the Independent Directors of the Company have given their
respective declaration / disclosures under Section 149(7) of the Companies Act, 2013
("the Act") and Regulation 25(8) of the Listing Regulations and have confirmed
that they fulfill the independence criteria as specified under section 149(6) of the Act
and Regulation 16 of the Listing Regulations and have also confirmed that they are not
aware of any circumstance or situation, which exist or may be reasonably anticipated, that
could impair or impact their ability to discharge their duties with an objective
independent judgment and without any external influence. Further, the Board after taking
these declarations/disclosures on record and acknowledging the veracity of the same,
concluded that the Independent Directors are persons of integrity and possess the relevant
expertise and experience to qualify as Independent Directors of the Company and are
Independent of the Management.
The Board opines that all the Independent Directors of the Company
strictly adhere to corporate integrity, possesses requisite expertise, experience and
qualifications to discharge the assigned duties and responsibilities as mandated by the
Companies Act, 2013 and Listing Regulations diligently
39. Directors and Officers Insurance
As per the requirements of Regulation 25(10) of the SEBI Listing
Regulations, the Company has taken Directors and Officers Insurance (D&O')
for all its Directors and members of the Senior Management.
40. Names of Companies, which have become or ceased to be
Company's Subsidiaries, Joint Ventures or Associate Companies during the year.
During the year under review, no Company has become or ceased to be
Company's Subsidiary, Joint Venture or Associate Company.
41. Designate Person for furnishing or providing information to the
Registrar of Companies with respect to beneficial interest in shares of the company.
Pursuant to Rule 9 of the Companies (Management and Administration)
Rules, 2014 and other applicable provisions of the Companies Act, 2013, the Board of
Directors of the Company designated Company Secretary of the Company for furnishing or
providing information to the Registrar of Companies with respect to beneficial interest in
shares of the company.
42. Transfer of Amounts to Investor Education and Protection Fund
Your Company did not have any funds lying unpaid or unclaimed for a
period of seven years. Therefore there were no funds that were required to be transferred
to the Investor Education and Protection Fund (IEPF).
43. Directors' Responsibility Statement
The Directors' Responsibility Statement referred to in clause (c)
of sub-section (3) of Section 134 of the Companies Act, 2013, shall state that:
a) In preparation of the annual financial statement for the year ended
March 31, 2026, applicable accounting standards have been followed along with proper
explanation relating to material departures if any;
b) Such accounting policies have been selected and applied consistently
and made judgments and estimates that are reasonable and prudent so as to give a true and
fair view of the state of affairs of the company as of March 31, 2026, and of the profit
of the Company for the year ended on that date;
c) Proper and sufficient care has been taken in the maintenance of
adequate accounting records in accordance with the provisions of the Companies Act 2013
for safeguarding the assets of the company and for preventing and detecting fraud and
other irregularities;
d) The annual accounts have been prepared on a going-concern basis; e)
Based on the framework of internal financial controls and compliance systems established
and maintained by the Company, work performed by the internal, statutory, and secretarial
auditors and external consultants, including audit of internal financial controls over
financial reporting by the statutory auditors and the reviews performed by management and
the relevant Board Committees, including the Audit, Risk Management Committee, the Board
is of the opinion that proper internal financial controls are in place and such internal
financial controls are adequate and are operating effectively.
f) Proper systems have been devised to ensure compliance with the
provisions of all applicable laws and such systems are adequate and are operating
effectively.
44. Acknowledgment
Your Directors place on record their gratitude to the Central
Government, State Governments and all other Government agencies for the assistance,
co-operation and encouragement they have extended to the Company.
Your Directors also take this opportunity to extend a special thanks to
the medical fraternity and patients for their continued cooperation, patronage and trust
reposed in the Company. Your Directors also greatly appreciate the commitment and
dedication of all the employees at all levels, that has contributed to the growth and
success of the Company.
Our Directors also thank all the strategic partners, business
associates, Banks, financial institutions and other stakeholders including the
shareholders for their assistance, co-operation and encouragement to the Company during
the year.
|
For and on behalf of the Board of
Directors of |
|
|
Krishna Institute of Medical Sciences
Limited |
|
|
Dr. Bhaskara Rao Bollineni |
Dr. Abhinay Bollineni |
| Place: Hyderabad |
Chairman & Managing Director |
Director & CEO |
| Date: 15.05.2026 |
(DIN No.00008985) |
(DIN No.01681273) |
|